Search results for " Relapser"

showing 2 items of 2 documents

Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomi…

2006

AIM: To assess the efficacy of different schedules of consensus interferon (CIFN) plus ribavirin in retreating chronic hepatitis C patients who relapsed after recombinant interferon (rIFN) monotherapy. METHODS: Forty-five patients (34 males and 11 females) with chronic hepatitis due to hepatitis C virus (HCV) genotype 1 who relapsed after a previous course of rIFN monotherapy were randomized to receive 9 μg CIFN three times per week for 52 wk (group A, n = 22) or 18 μg CIFN three times per week for 52 wk (group B, n = 23) in combination with ribavirin 800 to 1200 mg daily for 52 wk (according to body weight). Virological response was evaluated at week 24 (EVR), at the end of treatment (ETR)…

AdultMalemedicine.medical_specialtySettore MED/07 - Microbiologia E Microbiologia ClinicavirusesHepacivirusAlpha interferonHepacivirusPharmacologyGastroenterologyAntiviral AgentsDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled triallawInterferonRecurrenceInternal medicineRibavirinmedicineHumansIn patientSettore MED/12 - GastroenterologiabiologyDose-Response Relationship Drugbusiness.industryRibavirinGastroenterologyInterferon-alphaGeneral MedicineHepatitis C ChronicMiddle AgedViral Loadbiology.organism_classificationhumanitiesRecombinant ProteinsTreatment OutcomechemistryInterferon Type IInterferon Ribavirin Hepatitis C virus Hepatitis C RelapserDrug Therapy CombinationFemalebusinessViral loadInterferon type IRapid Communicationmedicine.drugWorld journal of gastroenterology
researchProduct

Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combin…

2010

There is a lack of information on the characteristics of patients with chronic hepatitis C virus infection (HCV) who fail to respond to antiviral treatment. We studied HCV-positive subjects with chronic liver diseases treated with pegylated-interferon (PEG-IFN) and ribavirin (RBV) who failed to clear HCV in routine clinical practice. A total of 2150 consecutive adult patients treated with PEG-IFN plus RBV therapy in 46 Italian centres between 1 July 2004, and 30 June 2005, were studied. Of the 2150 patients, 923 (42.9%) (M/F 585/335, mean age 54.8 years) failed to achieve a serum HCV-RNA clearance. Of these 923 patients, 429 (46.5%) were nonresponders, 298 (32.3%) relapsers, 168 (18.2%) dro…

AdultMalenon-responders.relapserGenotypebody mass index; cirrhosis; hepatitis c virus; nonresponder; pegylated-interferon; relapserInfectious Diseasebody mass indexHepacivirusvirusInterferon alpha-2Antiviral AgentsPolyethylene GlycolPolyethylene GlycolsMedication Adherencebody mass index; cirrhosis; hepatitis C; virus; nonresponder; pegylated-interferon; relapserRisk FactorsRetrospective StudienonresponderVirologyRibavirinHumansAge FactorTreatment FailureRetrospective StudiesAgedAntiviral AgentSettore MED/12 - GastroenterologiaHCV; Antiviral therapy; Body mass index; Cirrhosis; Hepatitis C virus; Nonresponder; Pegylated-interferon; RelapserCirrhosiHepaciviruHepatologyRisk FactorcirrhosisAge FactorsInterferon-alphahepatitis c virusHepatitis C ChronicMiddle AgedRecombinant ProteinRecombinant ProteinsItalyRNA ViralFemalehepatitis Cpegylated-interferonHepatitis C viruHuman
researchProduct